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Motivating Sample Sizes in Adaptive Phase I Trials via Bayesian Posterior
Credible Intervals
Thomas M. Braun
University of Michigan School of Public Health
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Summary: In contrast with typical Phase III clinical trials, there is little existing methodology for determining the
appropriate numbers of patients to enroll in adaptive Phase I trials. And, as stated by Dennis Lindley in a more
general context, ”[t]he simple practical question of ’What size of sample should I take’ is often posed to a statistician,
and it is a question that is embarrassingly difficult to answer.” Historically, simulation has been the primary option
for determining sample sizes for adaptive Phase I trials, and although useful, can be problematic and time-consuming
when a sample size is needed relatively quickly. We propose a computationally fast and simple approach that uses
Beta distributions to approximate the posterior distributions of DLT rates of each dose and determines an appropriate
sample size through posterior coverage rates. We provide sample sizes produced by our methods for a vast number
of realistic Phase I trial settings and demonstrate that our sample sizes are generally larger than those produced by
a competing approach that is based upon the nonparametric optimal design.
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1. Introduction
Phase I oncology trials of chemotherapeutic agents have had a conceptually simple goal: to
determine which doses of an agent can be given to patients before an unacceptable fraction,
0 < θ < 1, of patients begins to experience dose-limiting toxicities (DLTs). Statistically
speaking, we have an unknown dose-response curve, and we assign doses to patients and use
their data to identify the desired quantile θ on the curve while attempting to minimize the
number subjects exposed to highly toxic doses (Rosenberger and Haines, 2002).
There are numerous approaches for designing Phase I trials; see Table 1 of Braun (2014)
for examples. Our work focuses upon a specific design known as the Continual Reassessment
Method (CRM) (O’Quigley et al., 1990), which adopts a parametric model f(d; β), that is
monotonic in d to describe how the probability of DLT is related to dose d. The logistic
model f(d; β) = exp[3 + exp(β)d]/(1 + exp[3 + exp(β)d]) and the so-called “power” model
f(d; β) = dexp(β) are models commonly used in the CRM. The parameter β is given a prior
distribution with mean µ (usually µ = 0) and variance σ2 and support on the real line.
We sequentially update the posterior distribution of β as each enrolled subject or cohort of
subjects is observed for the occurrence of DLT. We use the resulting posterior distribution for
the probability of DLT for each dose to determine the dose assignment for the next cohort;
this assignment is usually the dose whose posterior probability of DLT is closest to θ. Final
mean posterior DLT probabilities for each dose are computed once all patients have been
observed; the MTD is often defined as the dose whose posterior mean probability is closest
to θ, although the MTD can be defined in other ways (Babb et al., 1998).
A competitor to the CRM is the 3+3 design (Storer, 1989), which is an algorithm that
determines acceptability of doses from the outcomes seen in three-patient cohorts. One of
the appealing features of the 3+3 design is its pre-determined maximum sample size of six
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no statistical motivation. In fact, the sample size used in 3+3 designs is often woefully
insufficient to provide evidence that the MTD has been correctly identified, motivating the
recent practice of enrolling additional patients at the proposed MTD in a so-called “expansion
cohort” (Boonstra et al., 2015; Iasonos and O’Quigley, 2016).
Certainly there are sample size formulae for a myriad of Phase III trial designs; even
Phase II trials using a Simon two-stage design (Simon, 1989) are provided with a sample size.
However, the crux of these methods lies in traditional hypothesis testing, in which explicit null
and alternative hypotheses are stated. In adaptive Phase I trials, although we certainly have
a model parameter, our primary goal is not based in inference for that parameter. Instead,
the model and parameter are simply used to facilitate a way to compare the probabilities
of toxicity of each dose in order to identify the MTD. Historically, simulation has been the
only real avenue for determining appropriate sample sizes for Phase I trials (Tighiouart and
Rogatko, 2012), although Cheung (2013b) recently developed the first systematic approach
to sample size determination specific to the CRM, the details of which will be presented in
Section 2.
Our work presents an alternative to the approach of Cheung (2013b), which is based
upon an asymptotic frequentist approximation. Instead, our approach is founded in Bayesian
sample size estimation, for which numerous prior research exists (Pham-Gia and Turkkan,
1992; Joseph et al., 1995; Pham-Gia, 1997; M’Lan et al., 2008). We will describe our approach
in Section 2 and demonstrate the results of our methods via simulation in Section 3, as well
as compare those results to those of Cheung (2013b). We will conclude with a summary and
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2. Methods
2.1 Notation
We have a set of J clinical doses, D1 < D2 < . . . < DJ , and wish to determine which of the
doses has a DLT rate closest to the targeted DLT rate θ. We let pj denote the DLT rate for
dose j = 1, 2, . . . J and assume that the pj can be modeled with a one-parameter function
of dose, f(Ej; β), in which β is the unknown parameter and Ej is a modified value of Dj
to encourage better model fit of f(·). The values E1, E2, . . . , EJ are based upon a vector of
a priori values known as the skeleton. Although there are a variety of ways of selecting a
skeleton and methods for averaging results over multiple skeletons (Yin and Yuan, 2009b),
we will use the methods of Lee & Cheung (Lee and Cheung, 2009) to define our skeleton,
which are implemented in the function getprior in the dfcrm library (Cheung, 2013a) created
for the statistical package R (R Core Team, 2016). In both the power model and the logistic
model, the parameter β is allowed to take any value on the real line. Thus, it is standard to
assume that the prior distribution for β, which we denote g(β), is Gaussian with mean zero
and variance σ2, with the value of σ2 treated as a design parameter whose value is fixed at
a specific value. Methods for determining appropriate values of σ2 have been proposed (Lee
and Cheung, 2011; Zhang et al., 2006).
Although the CRM was first proposed to assign the first patient at the a priori MTD
defined by the skeleton, it is now more accepted that the first subject be assigned to the
lowest dose to avoid concerns of overdosing early in the trial. The dose assigned to each
new subject i = 2, 3, . . . N is determined from the data collected on all previously enrolled
subjects. We let E[k], k = 1, 2, . . . , i − 1, denote the dose assignment for enrolled subject k,
which is among the values E1, E2, . . . , EJ , and let Yk = 1 and Yk = 0 indicate respectively
that subject k has or has not had a DLT. Before subject i is enrolled, we have a likelihood
Li−1(β | Y ,E) =
∏i−1
k=1 f(E[k]; β)
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posterior distribution
hi−1(β | Y ,E) =
Li−1(β | Y ,E)g(β)∫∞
−∞ Li−1(β | Y ,E)g(β)dβ
,
in which Y = {Y1, Y2, . . . , Yi−1} and E = {E[1], E[2], . . . , E[i−1]}. We then use h(β | Y ,E) to
compute µ̃i−1, the posterior mean of β, from which we obtain p̃ij = f(Ej; µ̃i−1), the posterior
estimate of the probability of DLT for dose j. Patient i is then assigned to the dose with p̃ij
closest to the target DLT rate θ, subject to possible dose assignment restrictions. We now
describe methods for determining how large N should be before terminating the trial.
2.2 Sample Size via Cheung (2013b)
For Phase I trials using the CRM, Cheung (2013b) determined a lower bound for the sample
size based on theoretic properties of what is known as the nonparametric optimal design
(NOD) (O’Quigley et al., 2002). The NOD is a simulation-based approach in which potential
DLT outcomes are generated for every patient for every dose, which contrasts with an actual
trial in which a single DLT outcome is observed for each patient at a specific dose. For a
given sample size N , the NOD estimates pj for each dose j from the observed proportion of
DLTs in the N simulated outcomes. Given that the NOD determines DLT rates using JN
observations, as well as the unbiased and minimum variance properties of sample proportions,
the performance of the NOD is viewed as a benchmark for the performance of any CRM
design that determines DLT rates from N observations. Thus, any sample size determined
from the nonparametric optimal design is seen as a lower bound for the needed sample size
of any CRM design.
As a result, using the asymptotic properties of the estimators used in the NOD, Cheung
(2013b) developed his sample size lower bound as follows. For a given number of doses J and
a targeted DLT rate θ,we first specify J vectors of hypothetical DLT rates P 1,P 2, . . .P J ,
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in vector k = 1, 2, . . . J . Each P k is defined such that












if j < k
for a given odds ratio R > 1. In other words, we have J settings, dose k is the true MTD
in setting k, and neighboring doses in each setting have DLT rates that differ from each
other through an odds ratio R. For each setting k, defined by P k, we could run simulations
to compute P̂CSk, an estimate for the probability of correct selection (PCS) of the MTD
when dose k is the MTD. We denote the metric AN(θ, J,R) =
∑J
k=1 P̂CSk/K, which is
the average PCS over all the settings examined. Typically we select N over a grid search of
possible values until AN(θ, J,R) reaches a desired threshold.









[2Φ{w1(θ, R,N) + w2(θ, R,N)} − 1] ,





θ − α1 + 0.5N−1√





α2 − θ − 0.5N−1√







Thus, for a given desired probability of correct selection, AN(θ, J,R), number of doses,
J , and variation in DLT rates, R, the corresponding sample size can be determined. As
expected, the necessary sample size will increase with increases in AN(θ, J,R) and J , and
will decrease with increases in R. Such a calculation is provided by the function getn in the
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We emphasize that this function is for a design in which the DLT rates are modeled via the
power model, with a prior variance of 1.34 for the model parameter, and assumes that the
first subject is assigned to the median dose value. We will use the sample sizes produced by
this function in Section 3 as a comparator for the sample sizes produced by our method,
which we describe next.
2.3 Bayesian Sample Size Determination
Recall that the CRM uses a one-parameter model pj = f(Ej; β) for the DLT rate of each dose
j and a prior distribution is placed on β. This prior distribution leads to a prior distribution
for each pj that often lacks a closed-form expression. We denote this prior distribution
as F(mj, vj) with prior mean mj and prior variance vj. Because each pj is a binomial
















The values of mj and vj can be approximated either through sampling directly from the the
prior of β and computing the resulting means and variances of each pj or by using a Taylor
series expansion. With N subjects receiving dose j, in whom we see Y DLTs, we know that
pj has a posterior Beta distribution with parameters aj + Y and bj + (N − Y ); we denote
this posterior distribution as fj(p | Y,N). See Morita et al. (2010) & Morita et al. (2012) for
use of this approximation in other settings.
For a vector of true DLT rates π = {π1, π2, . . . πJ} and the targeted DLT rate θ, we
define jθ as the index of the dose whose DLT rate is closest to θ, i.e. dose jθ is the true
MTD among the doses being studied. Note that in the methods of Cheung (2013b), π is
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exactly equal to θ. Our methods are applicable to any general vector of DLT rates, although
certainly an approximate odds ratio could be determined from a given vector of DLT rates
in order to apply the methods of Cheung (2013b).
We will use the location and spread of fjθ(p | Y,N) to help determine when N is “large
enough,” somewhat related to the stopping rule proposed by Ishizuka and Ohashi (2001).
Intuitively, as N grows larger, the posterior mean of pjθ will get closer to πjθ and the posterior
variance of pjθ will continually shrink. Likewise, the posterior distributions of the DLT rates
of all other doses will become more peaked around their respective true DLT rates. Thus, as
the sample size N increases, the posterior distributions will have less and less overlap with
each other, allowing for the determination of the MTD, which is dose jθ, with more and
more precision.
Our desired level of precision will be defined by two parameters φ and γ`. We define an
interval I∗ = θ±φ of acceptable DLT rates around the target θ. Intuitively, as φ gets larger
(smaller), the necessary sample size should decrease (increase). We propose that the value
for φ should be the average distance between the true DLT rates of adjacent doses, i.e. if all
the DLT rates differ from the doses directly adjacent to them by an average of 10 points,
then φ = 0.10. This metric is obviously related to the odds ratio R used by Cheung (2013b),
although we focus on the absolute differences between the true DLT rates rather than the
absolute difference of the log-odds of the true DLT rates.
The sample size formula of Cheung (2013b) varies with the number of doses J ; our approach
also will reflect the number of doses implicitly through the definition of φ. For example,
suppose we are studying five doses, and we assume the doses have true DLT rates of π =
{0.05, 0.12, 0.20, 0.30, 0.45}; currently φ would be equal to 0.10. If the study were expanded
to include a sixth dose, the value of φ will possibly change to reflect the location of the DLT
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of 0.55, then φ would remain at 0.10, which makes sense because this dose is even further
from the MTD than the fourth and fifth doses, so that few, if any patients would be assigned
to this dose and little additional information would be gleaned from including this dose. In
contrast, if the sixth dose had a true DLT of 0.35, we now have φ = 0.06, which would
lead to a much larger sample size because correctly identifying the MTD would require more
information than that required by the original five doses. We can consider our parameter φ
analogous to the parameter α, which is the false positive, or Type I error, rate considered in
traditional sample size calculations.
Given the interval I∗, we can compute γ(N, Y ) =
∫
I∗ fjθ(p | Y,N)dp, which is a posterior
interval probability (PIP) for dose jθ, specifically the amount of posterior mass for pjθ in the
interval I∗. Since this PIP is conditional upon the observed number of DLTs Y out of N
subjects, we compute γ(N) =
∑y=N
y=0 γ(N, y)Bin(N, pjθ), which is a weighted average of PIP
values over the density of Y , which has a binomial distribution with parameters N and pjθ .
Our second parameter, γ` defines the minimum amount of PIP we desire at the true MTD,
and is analogous to power, or the true positive rate, used in traditional sample sizes.
Thus, our sample size algorithm is as follows:
(1) Select J , the number of doses to be studied, θ, the targeted DLT rate, the dose-toxicity
model f(Ej; β) with corresponding skeleton values E1, E2, . . . EJ , and σ
2, the prior variance
for β;
(2) Determine the parameters of each beta distribution defined in Equations (1) and (2);




(4) Select a value for γ`, the minimum desired amount of mass in I∗ = (θ − φ, θ + φ) for the
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(5) Select a vector of possible sample sizesN , and for each value N ∈ N , compute the resulting
value of γ(N);
(6) Find the smallest value of N such that γ(N) > γ`.
As a practical example, suppose we have five doses under study and our targeted DLT rate
is θ = 0.30. We will use the power model with the model parameter β having a prior variance
of σ2 = 1.34. We have a vector of skeleton DLT rates {0.06, 0.16, 0.30, 0.45, 0.59} so that the
middle dose is the a priori MTD. The prior distribution for β places a prior mean and
variance on the DLT rates for each dose; we find the parameters of a beta distribution that
correspond to each mean and variance. For example, the prior mean and variance for the DLT
rate of the first dose are 0.17 and 0.05, respectively, which correspond to beta distribution
parameters a1 = 0.33 and b1 = 1.58 from Equations (1) and (2). Similar computations are
made for the remaining four doses.
The sample size is now a function of the actual DLT rates of the five doses and the desired
value of γ`, the posterior coverage level. Suppose the vector of true DLT rates for the five
doses is {0.05, 0.16, 0.28, 0.39, 0.50}, so that the average difference between adjacent DLT
rates is φ = 0.11. This defines an interval of I∗ = (θ − φ, θ + φ) = (0.19, 0.41) . Suppose we
now wish to find a sample size that supports a PIP of γ` = 0.70 in the interval (0.19, 0.41).
We simply iteratively examine a range of sample sizes until we find the smallest sample size
that achieves the desired PIP level. In this example, we obtain a sample size of N = 37. R
code for this calculation can be found in the Web Supplement.
If we were to change the true DLT rates to {0.10, 0.20, 0.30, 0.40, 0.50}, we now have a
value φ = 0.10, which results in a larger sample size of N = 45 because the value of φ is
now smaller than before. We could also return to our original setting and instead reduce the
prior variance of β in half to be σ2 = 0.67, which leads to smaller sample size of N = 35.
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the skeleton to be {0.00, 0.01, 0.06, 0.16, 0.30}, leading to a sample size of N = 37. These
two sample size values are practically identical to the original sample size of N = 37 and
demonstrate that the choices of prior variance and skeleton have much less impact on the
sample size than does the vector of true DLT rates.
3. Numerical Studies
We now compare and contrast the sample sizes produced by our method and by the method
of Cheung (2013b). We have J ∈ {4, 5, 6} doses under study and the targeted DLT rate
equal to θ ∈ {0.20, 0.25, 0.30}. We use the empiric model with a prior variance of 1.34 for the
model parameter, which is the default value in the R function crmsim. Skeleton values were
determined via the R function getprior (Lee and Cheung, 2011) using a half-width of θ/4, as
recommended in Cheung (2013b). The skeleton was computed assuming the third dose was
the MTD. True DLT rates are equally spaced from a value pmin ∈ {0.05, 0.10, 0.15, 0.20} to
a value pmax ∈ {0.3, 0.4, 0.5, 0.6, 0.7}, which combined with the selected values of J and θ,
determine the location of the MTD. Each of the settings defined by a combination of J , θ,
pmin, and pmax results in a value of φ for our proposed methods, as well as an approximate
odds ratio R necessary for the methods of Cheung (2013b). The value of R was approximated
as exp{logit(θ + φ)− logit(θ)}, where logit(x) = log(x)− log(1− x).
For each setting, we computed the necessary sample size using our methods for values of the
desired minimum posterior coverage γ` ∈ {0.6, 0.7, 0.8, 0.9}. We then ran 1,000 simulations
of Phase I trials designed with the CRM using each of the resulting sample sizes in order
to compute both the posterior distribution of the model parameter β as well as the dose
identified as the MTD at the end of the study. From these 1,000 simulations, we computed
the average posterior mass of the interval θ ± φ and P̂CS, the proportion of simulations in
which the MTD was correctly identified. We computed these values separately for studies
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(2013b), and for studies assigning the lowest dose to the first subject, which is more commonly
used in practice. We then used the value of P̂CS from each approach in the R function getn
in order to compute the suggested sample size from the methods of Cheung (2013b). Code for
generating the simulation results is available in the Web Supplement, although an R library
is being generated and will be made publicly available at the Comprehensive R Archive
Network (CRAN) when completed.
Due to space limitations, results for a subset of all the settings are presented in four
tables that can be found in the Web Supplement. There is one table for each for the four
possible values of γ`, and each table contains results for 24 settings. The same 24 settings
are summarized in each of the four tables so that corresponding rows in each table can be
directly compared to each other to observe how the sample size increases with γ`.
Figure 1 provides a visual summary of the results when γ` = 0.60 (left panels) and γ` = 0.70
(right panels). Each of the six panels provides a range of a sample sizes produced using our
proposed method, as well as a corresponding range of sample sizes computed using the
method of Cheung (2013b) that have the same probability of correct selection (P̂CS) as our
method. Each panel also provides the actual average coverage rate produced by the sample
size from our method. For example, the upper left-hand plot in Figure 1 demonstrates that
with four doses, our method produces sample sizes ranging from 13 to 18 subjects, with an
actual coverage rate of 0.70 and P̂CS = 0.44. The corresponding sample sizes from Cheung’s
method range from 5-6 subjects.
In all six panels of Figure 1, we can draw some general conclusions. First, we see that for a
given probability of correct selection, our method suggests that the sample sizes of Cheung
(2013b) are too small, which we expect. Second, the actual coverage rates are a bit higher
than the desired value, but are generally close enough to suggest the beta distributions
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invariant to the targeted DLT rate θ, (b) increases when the desired coverage rate increases,
and (c) increases slightly as the number of doses increases. Last, there are suggestions that
a desired coverage rate of γ` corresponds to a probability of correct selection that is about
20 points lower, i.e. γ` = 0.60 corresponds roughly to P̂CS = 0.40.
[Figure 1 about here.]
Figure 2 provides a visual summary of the results when γ` = 0.80 (left panels) and γ` = 0.90
(right panels) and supports the conclusions reached from Figure 1. We do see in Figure 2
that there is a smaller difference between the sample sizes produced by our method and by
Cheung (2013b) than seen in Figure 1, although the sample sizes of Cheung (2013b) remain
lower than what is needed for the given value of P̂CS. From the sample size values in Figure
2, we also see that a desired coverage rate of 0.80 or higher requires a sample size larger than
what is actually used in most trials.
[Figure 2 about here.]
4. Discussion
Our work supports the growing body of research demonstrating the superiority of adaptive
designs to algorithmic ones (Iasonos et al., 2008; Jaki et al., 2013) and suggests that the
sample sizes used in actual Phase I trials are likely insufficient for finding a chemotherapy
dose that will be used in future Phase II trials. We note that, for a resulting sample size
N , our methods have implicitly assumed that all N subjects have been treated at the true
MTD, with no patients treated at the other doses. This contrasts to the actual design of
an adaptive trial, in which roughly 50% of patients would be treated at the MTD, with
fewer patients treated at doses directly above and below the MTD and even fewer patients
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Although our methods have not assumed a “greedy” dose-assignment algorithm, in which
each patient or cohort of patients is assigned to the dose currently believed to be the MTD,
our methods do require that the CRM will be consistent (Cheung and Chappell, 2002; Shen
and O’Quigley, 1996). In other words, dose assignments cannot get “stuck” at a non-MTD
dose ad infinitum, so that correctly identifying the MTD does not improve with sample size
(Oron and Hoff, 2011; Azriel et al., 2011). We did examine our methods with settings in
which the CRM has been shown to not be consistent, and found that the resulting sample
sizes, which were unusually large (in the range of 300 to 500 subjects), led to a much smaller
coverage rate than that desired. Thus, when our method suggests that hundreds of subjects
will be necessary, there is a warning that non-consistency of the CRM could be an issue,
which can be determined easily with the methods of Cheung and Chappell (2002).
We would like to expand our methods to other designs, such as combination trials of
two agents (Yin and Yuan, 2009a; Braun and Jia, 2013; Mander and Sweeting, 2015) and
partial follow-up of toxicity outcomes (Cheung and Chappell, 2000; Yuan and Yin, 2011).
We hope that our methods provide a springboard from which appropriate sample sizes can
be determined for these more complex and contemporary adaptive Phase I trial designs.
5. Supplementary Materials
Web Appendices concerning R code and the tables referenced in Section 3 are available with
this paper at the Biometrics website on Wiley Online Library.
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Figure 1. Ranges of sample sizes produced by proposed method (Braun) and that of
Cheung (2013b), for studies of four doses (row 1), five doses (row 2) and six doses (row 3),
with desired coverage rates of γ` = 0.60 (column 1) and γ` = 0.70 (column 2). The value
above the ranges for Braun’s method is the actual coverage rate, while the value above the
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Figure 2. Ranges of sample sizes produced by proposed method (Braun) and that of
Cheung (2013b), for studies of four doses (row 1), five doses (row 2) and six doses (row 3),
with desired coverage rates of γ` = 0.80 (column 1) and γ` = 0.90 (column 2). The value
above the ranges for Braun’s method is the actual coverage rate, while the value above the
ranges for Cheung’s method is the actual probability of correct selection (PCS).
